Semaglutide vs MOTS-c
Head-to-head comparison of Semaglutide and MOTS-c for research applications. Both peptides are studied for Metabolic Health, but they differ significantly in mechanism, evidence level, and dosing protocols.
Side-by-Side Comparison
| Attribute | Semaglutide | Mots C |
|---|---|---|
| Category | Metabolic / GLP-1 Agonist | Metabolic / Mitochondrial |
| Mechanism | Semaglutide mimics the GLP-1 hormone by binding to GLP-1 receptors on pancreatic beta cells (glucose-dependent), brain (hypothalamus appetite centers), stomach, and intestines. | MOTS-c activates AMPK by inhibiting the folate cycle, causing accumulation of AICAR (an AMP analog). |
| Evidence Rating | A — FDA Approved | D — Preclinical |
| Clinical Status | FDA-approved (Ozempic for T2D, Wegovy for obesity) | Research-only / No human clinical trials completed (Phase 1 of analog CB4211 only) |
| Safety Profile | Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient); Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness | No adverse effects reported in preclinical animal studies; Human tolerability is completely unknown for native MOTS-c (no completed human trials) |
| Route | Subcutaneous (weekly injection); Oral tablet available (Rybelsus) | Subcutaneous |
| Dose Range | SC: 0.25–2.4 mg/week titrated over 16 weeks; Oral: 3–14 mg/day | 5–10 mg SC per injection |
| Frequency | Once weekly (SC); Once daily (oral) | Once daily or 3–5x weekly |
| Molecular Weight | ~4113.6 g/mol | ~2174.6 g/mol |
| Half-Life | ~160–168 hours (~7 days) | Several hours; tissue effects may persist longer |
Overview
Semaglutide and MOTS-c are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Semaglutide — Mechanism & Evidence
It is approved for type 2 diabetes (Ozempic), chronic weight management (Wegovy), and non-cirrhotic MASH (Wegovy). There is no generic semaglutide available, and the FDA has warned about counterfeit products.
Key claims: Causes significant weight loss; Improves blood sugar control; Reduces cardiovascular risk.
BPC-157 5mg
5mg
MOTS-c — Mechanism & Evidence
MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA-c) is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA gene (MT-RNR1). Discovered in 2015 by Lee et al. at USC, it acts as a metabolic regulator primarily through AMPK activation. In mouse models, MOTS-c prevents diet-induced obesity and insulin resistance, enhances exercise capacity (old mice ran 2x longer on treadmill tests), and reduces age-related metabolic decline. A modified analog (CB4211) showed good tolerability in a Phase 1 human trial. No clinical trials of native MOTS-c in humans have been completed.
Key claims: Improves insulin sensitivity and glucose metabolism; Exercise mimetic effects; Anti-obesity effects.
Shared Research Applications
Both peptides are studied for: Metabolic Health.
Semaglutide is also researched for: Weight Management, Cardiovascular.
MOTS-c is also researched for: Anti-Aging.
Safety Considerations
Semaglutide: Common (5%+ in trials): nausea, vomiting, diarrhea, abdominal pain, constipation (usually dose-dependent and transient) Additional common effects: upset stomach, heartburn, burping, gas, bloating, loss of appetite, headache, dizziness, tiredness Serious but rare: pancreatitis, gallbladder disease, severe allergic reactions (hives, swelling, difficulty breathing)
MOTS-c: No adverse effects reported in preclinical animal studies Human tolerability is completely unknown for native MOTS-c (no completed human trials) Modified analog CB4211 showed good tolerability in Phase 1
Shop Research Peptides
BPC-157 5mg
5mg
Retatrutide 20mg
20mg
Retatrutide 10mg
10mg
GHK-Cu 50mg
50mg
Tesamorelin 10mg
10mg
BPC-157 10mg
10mg
Tirzepatide 10mg
10mg
Quality Documentation
Review batch documentation before making research purchasing decisions. Volta pairs product education with COA literacy so researchers can evaluate purity, identity, lot details, and testing context.
Product cards on this page link to current catalog entries and available quality documentation.
Related Research News
Semaglutide News: New Meta-Analysis Highlights Weight and Inflammatory Benefits
A recent systematic review and meta-analysis examines the effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes. Early reports suggest meaningful reductions in body weight alongside improvements in inflammatory biomarkers, offering new context for peptide researchers and industry professionals.
MOTS-c Half-Life: What Studies Show and What Remains Unknown
This reference clarifies what primary studies have established about MOTS-c half-life and stability, and identifies the pharmacokinetic questions that remain unanswered in humans.
Semaglutide News: How Long to Lose 30 Pounds on Semaglutide?
A common question in the semaglutide news cycle is how long it takes to lose 30 pounds on the medication. While individual results vary, clinical trial data and prescribing guidelines offer a general timeline. This article breaks down the expected weight loss trajectory and what factors influence the pace.
Peptide Tools
Follow Research Updates
Get new research pages, product updates, tool releases, and quality resources from Volta.
Subscribe